Plandaí Biotechnology, Inc. (PLPL) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerPlandaí Biotechnology, Inc. (PLPL) trades at $0.0001. Plandaí Biotechnology, Inc. is focused on developing botanical extracts for the nutraceutical and pharmaceutical industries. The company cultivates green tea and other crops in South Africa, aiming to produce proprietary compounds. Sector: Financials.
Price as of · Last analyzed: Mar 17, 2026Analyst Coverage for PLPL: PLPL does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Plandaí Biotechnology, Inc. (PLPL) Financial Services Profile
Plandaí Biotechnology, Inc. is a shell company focused on botanical extract development for nutraceutical and pharmaceutical applications. The company cultivates green tea and other crops in South Africa, aiming to produce proprietary compounds like Phytofare Catechin Complex. It operates within the financial services sector, facing competition and market volatility.
What Is the Investment Thesis for PLPL?
Plandaí Biotechnology, Inc. presents a speculative investment opportunity due to its focus on developing proprietary botanical extracts. The company's success hinges on the successful development and commercialization of its Phytofare Catechin Complex and other extracts. Key value drivers include the potential market demand for its nutraceutical and pharmaceutical products. However, the company faces significant risks, including the challenges of obtaining regulatory approvals, scaling production, and competing with established players in the nutraceutical and pharmaceutical industries. With a negative P/E ratio of -5.89 and a Beta of 9.73, the stock exhibits high volatility and potential for losses.
Based on FMP financials and quantitative analysis
PLPL Key Highlights
Market capitalization of $0.00B, indicating a micro-cap company with limited financial resources.
- Negative P/E ratio of -5.89, reflecting current unprofitability.
- Beta of 9.73, suggesting extremely high volatility compared to the overall market.
- No dividend yield, indicating that the company is not currently returning capital to shareholders.
- Focus on developing proprietary botanical extracts, a high-risk, high-reward business model.
Who Are PLPL's Competitors?
PLPL is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| FUNR Funr | $1.00 | +376.19% | $10.0B | — |
| APXT Apex Technology Acquisition Corp. | $10.15 | 0.00% | $1.89B | 72 5-pillar |
| UMAC UMAC | $22.37 | +2.71% | $1.07B | 30 5-pillar |
| CEPF Cantor Equity Partners IV, Inc. | $10.27 | 0.00% | $471M | 51 5-pillar |
| KFII K&F Growth Acquisition Corp. II Class A Ordinary shares | $10.70 | +0.14% | $420M | 50 5-pillar |
| TACO Berto Acquisition Corp. | $10.46 | -0.10% | $392M | 52 5-pillar |
| TACH Titan Acquisition Corp. | $10.54 | -0.05% | $363M | 46 5-pillar |
| CCII Cohen Circle Acquisition Corp. II | $10.31 | +0.10% | $358M | 49 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PLPL's Key Strengths?
Proprietary botanical extracts under development.
- Senteeko Tea Estate provides a source of raw materials.
- Diversified product portfolio with timber and agricultural products.
- Experienced management team.
What Are PLPL's Weaknesses?
Limited financial resources.
- Negative P/E ratio indicates current unprofitability.
- High beta suggests high volatility.
- Reliance on successful development and commercialization of botanical extracts.
What Are the Key Risks for PLPL?
Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Failure to obtain regulatory approvals.
- Delays in product development and commercialization.
- Intense competition in the nutraceutical and pharmaceutical industries.
- Limited financial resources.
- High volatility due to OTC market listing.
What Threats Does PLPL Face?
- Intense competition in the nutraceutical and pharmaceutical industries.
- Stringent regulatory requirements.
- Potential delays in product development and commercialization.
- Fluctuations in commodity prices for timber and agricultural products.
What Are PLPL's Competitive Advantages?
- Proprietary botanical extracts: The company's Phytofare Catechin Complex and other extracts may offer unique health benefits.
- Senteeko Tea Estate: The company's tea estate in South Africa provides a source of raw materials.
- Diversified product portfolio: The company's involvement in timber and agricultural products provides diversification.
What Does PLPL Do?
Plandaí Biotechnology, Inc., based in London, United Kingdom, is a shell company focused on the production of proprietary botanical extracts targeting the nutraceutical and pharmaceutical industries. The company's primary focus is on developing Phytofare Catechin Complex, a botanical extract derived from green tea harvested from its Senteeko Tea Estate located in Mpumalanga, South Africa. Additionally, Plandaí Biotechnology is developing Phytofare citrus complex, a citrus extract, and exploring extracts from tomato fruit, Artemisia, and cannabis. Beyond botanical extracts, the company also engages in the production and sale of timber and agricultural products sourced from its farm and tea estate holdings in South Africa. This diversified approach aims to leverage its agricultural assets while pursuing high-value opportunities in the health and wellness sectors. The company operates with 180 employees.
What Products and Services Does PLPL Offer?
- Develop proprietary botanical extracts for the nutraceutical and pharmaceutical industries.
- Cultivate green tea at the Senteeko Tea Estate in South Africa.
- Produce Phytofare Catechin Complex, a green tea extract.
- Develop Phytofare citrus complex, a citrus extract.
- Explore extracts from tomato fruit, Artemisia, and cannabis.
- Produce and sell timber and agricultural products from its farm and tea estate holdings in South Africa.
How Does PLPL Make Money?
- Developing and selling proprietary botanical extracts to nutraceutical and pharmaceutical companies.
- Cultivating and processing green tea and other crops at its South African estate.
- Generating revenue from the sale of timber and agricultural products.
What Industry Does PLPL Operate In?
Plandaí Biotechnology, Inc. operates within the financial services sector, specifically as a shell company. The nutraceutical and pharmaceutical industries are characterized by intense competition, stringent regulatory requirements, and significant research and development costs. The company's success depends on its ability to differentiate its products, secure regulatory approvals, and establish strong distribution channels. The market for botanical extracts is growing, driven by increasing consumer demand for natural health products. However, Plandaí Biotechnology faces competition from established players with greater resources and expertise.
Who Are PLPL's Key Customers?
- Nutraceutical companies seeking botanical extracts for dietary supplements.
- Pharmaceutical companies interested in botanical extracts for drug development.
- Consumers purchasing timber and agricultural products.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
Plandaí Biotechnology, Inc. operates in the Shell Companies industry within the Financial Services sector. It is headquartered in Taipei, TW. PLPL has traded publicly since 1995.
Financial Health
Plandaí Biotechnology, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Insider Activity
11 transactions · 0 purchases, 0 sales, 11 other transactions · 5 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
PLPL Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
PLPL Latest News
No recent news available for PLPL.
PLPL Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for PLPL.
Price Targets
Wall Street price target analysis for PLPL.
PLPL MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for PLPL; grades run from A+ (80-100) to F (below 30).
Leadership: Roger Baylis-Duffield
CEO
Roger Baylis-Duffield is the CEO of Plandaí Biotechnology, Inc. He is responsible for managing 180 employees. His background includes experience in the agricultural and botanical extract industries. He has a proven track record of leading and growing companies in emerging markets. His expertise lies in strategic planning, operational management, and business development. He is committed to driving innovation and creating value for shareholders.
Track Record: Under Roger Baylis-Duffield's leadership, Plandaí Biotechnology has focused on developing its Phytofare Catechin Complex and expanding its agricultural operations in South Africa. He has overseen the company's efforts to secure regulatory approvals and establish strategic partnerships. His focus is on building a sustainable and profitable business model.
PLPL OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, encompassing stocks that are not current in their reporting requirements or do not meet the minimum qualifications for the higher tiers (OTCQX and OTCQB). Companies in this tier may be subject to limited regulatory oversight and may not provide regular financial disclosures, increasing the risk for investors compared to companies listed on major exchanges like the NYSE or NASDAQ. This tier often includes shell companies, defunct businesses, or companies with questionable operations.
- OTC Tier: OTC Other
- Limited or no financial disclosures.
- High risk of fraud or manipulation.
- Low liquidity and wide bid-ask spreads.
- Potential for delisting or going dark.
- Lack of regulatory oversight.
- Verify the company's registration and legal status.
- Review any available financial statements and disclosures.
- Assess the company's business model and revenue sources.
- Research the background and experience of the management team.
- Check for any regulatory actions or legal disputes.
- Monitor trading volume and price activity.
- Consult with a qualified financial advisor.
- Presence of a verifiable business address and contact information.
- Existence of a functional website with detailed information about the company.
- Independent audits of financial statements (if available).
- Positive news coverage or industry recognition.
- Active engagement with shareholders and the investment community.
Common Questions About PLPL (Financials)
What do analysts say about PLPL stock?
As of 2026-03-17, there is no available analyst coverage for Plandaí Biotechnology, Inc. due to its status as an OTC-listed shell company with a market capitalization of $0.00B.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market data may be limited or unreliable.